Quick Answer
TransMedics Group, Inc. reported Gross Profit of $362.81 million for the year ending 2025.
- TransMedics Group, Inc. showed an increase of +38.4% in Gross Profit from 2024 to 2025.
- This data is from TransMedics Group, Inc.'s annual report (Form 10-K), filed with the SEC on February 24, 2026.
- XBRL data for this metric is available from 2018 to 2025 (8 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2018: $924.0 thousand | Q2 2018: $1.18 million | Q3 2018: $2.13 million | Q4 2018: $1.50 million | Q1 2019: $2.57 million | Q2 2019: $3.33 million | Q3 2019: $4.22 million | Q4 2019: $3.74 million | Q1 2020: $4.86 million | Q2 2020: $1.91 million | Q3 2020: $5.04 million | Q4 2020: $4.83 million | Q1 2021: $4.81 million | Q2 2021: $5.59 million | Q3 2021: $3.77 million | Q1 2022: $12.10 million | Q2 2022: $14.35 million | Q3 2022: $18.12 million | Q1 2023: $28.77 million | Q2 2023: $36.74 million | Q3 2023: $40.66 million | Q1 2024: $59.96 million | Q2 2024: $69.26 million | Q3 2024: $60.85 million | Q1 2025: $88.23 million | Q2 2025: $96.59 million | Q3 2025: $84.58 million.
- Over the full 8 years of available data (2018 to 2025), TransMedics Group, Inc.'s Gross Profit has grown by 6,227.3%.
- Historical annual values: Fiscal year 2025: $362.81 million | Fiscal year 2024: $262.08 million | Fiscal year 2023: $154.09 million | Fiscal year 2022: $65.27 million | Fiscal year 2021: $21.16 million | Fiscal year 2020: $16.64 million | Fiscal year 2019: $13.86 million | Fiscal year 2018: $5.73 million.
- Data sourced from SEC EDGAR public filings as of August 9, 2026.
Last verified: